Daiichi Sankyo
OTC:DSNKYPharmaTokyo, Japan, Japan · Est. 2005 · 16,000 employees
Daiichi Sankyo is a Japanese pharmaceutical company focused on developing innovative medicines in oncology, cardiovascular, and immunological disease areas.
21
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
22
Indications↗
Distinct diseases across all programs
448
Clinical Trials↗
All sponsored trials (all statuses)
25
Orange Book Patents
Across 3 drugs with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
21 drugs in development
Phase 34
Phase 24
Phase 19
Preclinical8
By Therapeutic Area
top 3
Oncology
1983%
Rare Disease
14%
Neurology
14%
R&D Momentum
75/100
Pipeline Velocity
47/100
Trial Completion Rate
87/100
Pipeline Concentration
69/100
Pipeline Freshness
66/100
Strategic Signals
- ↗Active in Rare Disease but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 19, 2026
Recruiting
A Phase 1, Open-label, Multicenter, First-in-Human Trial of DS3610a in Participants With Advanced Solid Tumor
Sep 18, 2026
Recruiting
HERTHENA-PanTumor01 (U31402-277): A Phase 2, Multicenter, Multicohort, Open-Label, Proof of Concept Study of Patritumab Deruxtecan (HER3-DXd; U3-1402) in Subjects With Locally Advanced or Metastatic Solid Tumors
Sep 17, 2026
Recruiting
A Phase 2, Multicenter, Randomized, Open-label Trial to Evaluate Safety and Efficacy of Two Dose Levels of Quizartinib as Maintenance for Adult Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia in Complete Remission
Sep 16, 2026
Recruiting
A Phase 3, Multicenter, Randomized, Open-label Trial of Trastuzumab Deruxtecan in Combination With Pembrolizumab Versus Platinum-based Chemotherapy in Combination With Pembrolizumab, as First-line Therapy in Participants With Locally Advanced Unresectable or Metastatic HER2 Overexpressing and PD-L1 TPS <50% Non-squamous Non-small Cell Lung Cancer (DESTINY-Lung06)
Sep 16, 2026
Active, not recruiting
A Phase 1b, Multicenter, Open-Label Study of Valemetostat Tosylate in Combination With DXd ADCs in Subjects With Solid Tumors
Sep 9, 2026
Recruiting
A Phase I Study of DS-8201a in Combination With Olaparib in HER2-Expressing Malignancies
Earlier
Sep 5, 2026TrialPhase 1, Open-Label, Multicenter, First-In-Human Trial of Ds-2243a in Participants With Advanced Solid Tumors
Sep 5, 2026TrialPhase I, Two-Part, Multi-Center, First-in-Human Study of DS-6000a in Subjects With Advanced Renal Cell Carcinoma and Ovarian Tumors
3 more events
Sep 3, 2026TrialA Phase 1, Open-label, Multicenter, First-in-Human Trial of DS5361b in Participants With Advanced Solid Tumors
Sep 3, 2026TrialMedical Access Program for Ifinatamab Deruxtecan (I-DXd, DS-7300a)
Sep 2, 2026TrialHERTHENA-Lung01: A Phase 2 Randomized Open-Label Study of Patritumab Deruxtecan (U3-1402) in Subjects With Previously Treated Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer (NSCLC)
Details
Company Info
Company Overview
$50.0B
Mkt Cap
$9.0B
Revenue
—
Cash
CEOMasao Uchibori
Founded2005
Employees16,000
HQTokyo, Japan, Japan
ExchangeOTC:DSNKY
Websitedaiichisankyo.com
LinkedInCompany Page
Therapeutic Focus
CardiovascularMusculoskeletalOtherNeurologyNephrologyHematologyGastroenterologyOncologyInfectious DiseaseMetabolic & EndocrineRespiratoryRare DiseaseImmunology
Pipeline
Drug Pipeline
Therapeutic Area
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Neurology(1 drug)
1
—
—
—
—
Neurology(1 drug)
Oncology(19 drugs)
7
8
3
4
—
Oncology(19 drugs)
Rare Disease(1 drug)
—
—
1
—
—
Rare Disease(1 drug)
Unknown / Other(2 drugs)
1
1
1
—
—
Unknown / Other(2 drugs)
Regulatory
Regulatory Timeline
20152 events
FDAJan 8
Savaysa — SAVAYSA
Application NDA206316 (NDA)
FDAJan 8
Savaysa — SAVAYSA
Application NDA206316 (NDA)
20191 event
FDADec 20
ENHERTU — ENHERTU
Application BLA761139 (BLA)
20221 event
FDAOct 14
Turalio — TURALIO
Application NDA211810 (NDA)
20232 events
FDAJul 20
Vanflyta — VANFLYTA
Application NDA216993 (NDA)
FDAJul 20
Vanflyta — VANFLYTA
Application NDA216993 (NDA)
20252 events
FDAJan 17
DATROWAY — DATROWAY
Application BLA761394 (BLA)
FDAJan 17
DATROWAY — DATROWAY
Application BLA761394
20261 event
FDAMay 22
DATROWAY — DATROWAY
Application BLA761394
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)